IP Library Granted Patent US 8,679,549
Granted Patent B2
US 8,679,549 · App. 13/539,092 · Granted Mar 25, 2014

Electrolyte purgative

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,679,549
App. No.
13/539,092
Granted
Mar 25, 2014
Kind
B2
Abstract

The invention relates to compositions for use in purgatives, to purgatives comprising such compositions, and to methods for inducing purgation of the colon. The composition may comprise at least one water-soluble sodium salt; at least one water-soluble minimally degradable sugar in an amount, by weight, of from about 1 to about 3 times the weight of sodium ions in said composition; at least one water-soluble potassium salt in an amount, by weight, of from about 0.05 to about 1 time the weight of said sodium salt in said composition; and at least one water-soluble magnesium salt, wherein the weight of magnesium ions in said composition is from 0.1 to about 10 times the weight of sodium ions in said composition.

Claims (35)

1. A method of inducing purgation of the colon of a patient in need thereof, comprising administering to the patient a purgative composition in an amount effective to induce purgation of the patient's colon, wherein the purgative composition comprises:

a purgative composition comprising:

(i) 1-10 gram per unit dose of at least one water-soluble sodium salt;

(ii) 2-20 gram per unit dose of at least one water-soluble minimally degradable sugar;

(iii) 0.5 to 5 gram per unit dose of at least one water-soluble potassium salt;

(iv) 1-10 gram per unit dose of at least one water-soluble magnesium salt; and

(v) a detergent stool softening agent;

wherein the composition is a hypertonic composition in the form of a unit dose having a volume of from about 0.2 to 0.5 L,

and wherein the minimally degradable sugar comprises a xylose, a xylotriose, a mannitol, or a mixture thereof.

2. The method of claim 1 , wherein the water-soluble sodium salt is selected from the group consisting of sodium chloride, sodium gluconate, sodium citrate, sodium aspartate and mixtures thereof.

3. The method of claim 1 , wherein the water-soluble potassium salt is selected from the group consisting of potassium chloride and potassium tartrate and mixtures thereof.

4. The method of claim 1 , wherein the water-soluble magnesium salt is selected from the group consisting of magnesium sulfate, magnesium citrate and magnesium phosphate and mixtures thereof.

5. The method of claim 1 , wherein the detergent stool softening agent is a sodium picosulfate, a bisacodyl or a combination thereof.

6. The method of claim 1 , further comprising at least one composition or additive selected from the group consisting of a flavoring ingredient, citrate, lactate, acetate, a trace element and a nutritional element.

7. The method of claim 1 , further comprising a flavoring ingredient, a citrate, a lactate, an acetate, a trace element and a nutritional element.

8. The method of claim 1 , wherein the purgative composition is in the form of, or formulated as, a fluid, a soup or soup-like composition, tablet, gel cap, capsule or sachet.

9. The method of claim 1 , wherein: (i) the at least one water-soluble sodium salt comprises sodium chloride; (ii) the at least one water-soluble minimally degradable sugar comprises a xylose; (iii) the at least one water-soluble potassium salt comprises a potassium chloride; or (iv) the at least one water-soluble magnesium salt comprises magnesium sulfate.

10. The method of claim 1 , further comprising one or more compositions or additives selected from the group consisting of a citrate, a lactate, an acetate, a calcium, a zinc, a Vitamin B complex, a thiamine, a Vitamin A, a Vitamin C, a Vitamin E, a folic acid and a biotin.

11. The method of claim 1 , wherein the purgative composition is in the form of a tablet.

12. The method of claim 1 , wherein the purgative composition is in the form of a tablet comprising a core comprising the sodium, potassium and magnesium salts.

13. The method of claim 1 , wherein the purgative composition is in the form of a tablet comprising a coating comprising the minimally degradable sugar.

14. The method of claim 1 , wherein the purgative composition is in the form of a tablet comprising: a core comprising the sodium, potassium and magnesium salts; and a coating comprising the minimally degradable sugar(s); wherein the coating surrounds the core.

15. The method of claim 1 , wherein the at least one water-soluble sodium salt comprises a sodium chloride, a sodium gluconate, a sodium citrate or a sodium aspartate; the at least one water-soluble potassium salt comprises a potassium chloride; and the at least one water-soluble magnesium salt comprises a magnesium sulfate, a magnesium citrate or a magnesium phosphate.

16. The method of claim 1 , wherein the

weight of the water-soluble potassium salt in the composition is from about 0.05 to about 1 times the weight of the sodium salt in the composition; and

the weight of magnesium salt in the composition is from about 0.1 to about 10 times the weight of the sodium salt in the composition.

17. The method of claim 1 , wherein the purgative composition is administered in combination with a sodium picosulfate or a bisacodyl.

18. A method of inducing purgation of the colon of a patient in need thereof, comprising administering to the patient a purgative composition in an amount effective to induce purgation of the patient's colon, wherein the purgative composition comprises:

a purgative composition comprising:

(i) 1-10 gram per unit dose of at least one water-soluble sodium salt;

(ii) 2-20 gram per unit dose of at least one water-soluble minimally degradable sugar;

(iii) .5 to 5 gram per unit dose of at least one water-soluble potassium salt; and

(iv) 1-10 gram per unit dose of at least one water-soluble magnesium salt;

wherein the composition is a hypertonic composition in the form of a unit dose having a volume of from about 0.2 to 0.5 L,

and wherein the minimally degradable sugar comprises a xylose, a xylotriose, a mannitol, or a mixture thereof.

Assignments (10)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2020
From: SALIX PHARMACEUTICALS, INC.
To: RITE-PREP PTY LTD AS TRUSTEE FOR THE RITE-PREP UNIT TRUST
Reel/Frame 054065/0479 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2020
From: SALIX PHARMACEUTICALS, INC.
To: RITE-PREP PTY LTD AS TRUSTEE FOR THE RITE-PREP UNIT TRUST
Reel/Frame 054045/0216 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY AGREEMENT Recorded Apr 2, 2015
From: GLYCYX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 035364/0396 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2014
From: BORODY, THOMAS JULIUS; RAMRAKHA, SANJAY; SAXON, JOHN; WETTSTEIN, ANTONY
To: SALIX PHARMACEUTICALS, INC.
Reel/Frame 032933/0534 →